XML 53 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue from Contracts with Customers (Tables)
12 Months Ended
Dec. 31, 2024
Revenue from Contracts with Customers  
Summary of product revenue provision and allowance categories

    

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2021

$

142,379

$

54,617

$

13,226

Acquired from BDSI

38,074

18,187

7,575

Provision related to current period sales

497,250

38,250

132,547

Changes in estimate related to prior period sales

(619)

2,505

(592)

Credits/payments made

(520,147)

(40,005)

(130,698)

Balance as of December 31, 2022

$

156,937

$

73,554

$

22,058

Provision related to current period sales

424,013

41,993

149,976

Changes in estimate related to prior period sales

(4,802)

4,268

555

Credits/payments made

(426,322)

(42,310)

(151,672)

Balance as of December 31, 2023

$

149,826

$

77,505

$

20,917

Acquired from Ironshore

43,065

67,859

4,993

Provision related to current period sales

445,875

55,211

179,314

Changes in estimate related to prior period sales

372

1,962

(86)

Credits/payments made

(447,630)

(55,403)

(166,626)

Balance as of December 31, 2024

$

191,508

$

147,134

$

38,512

(1)Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s consolidated balance sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.
(3)Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s consolidated balance sheets.
Schedule of disaggregation of revenue

Years Ended December 31,

2024

2023

2022

Belbuca

$

211,269

$

182,095

$

126,461

Xtampza ER

191,330

    

177,374

    

138,804

Nucynta IR

100,740

108,150

112,058

Nucynta ER

75,767

82,653

72,418

Jornay

37,239

Symproic

15,104

16,495

12,267

Other

1,925

Total product revenues, net

$

631,449

$

566,767

$

463,933